Written and maintained by CASRAI Editorial Board
Published
On this page
An IRT system (interactive response technology) is the validated computer system a clinical trial uses to manage randomisation, the supply of investigational medicinal product (IMP) and, in blinded studies, controlled unblinding. The European Medicines Agency’s guideline on computerised systems in clinical trials lists IRT among the systems used “for the management of randomisation, supply and receipt of IMP, e.g. via a web based application.”
This page covers the clinical-trial meaning only. Its added value is a checklist of what regulators expect a sponsor to test and control in an IRT system, taken from the EMA guideline (Annex 5, section A5.2) and ICH E6(R3), set out in the data table below the article.
What does IRT stand for in research?
In clinical research IRT stands for interactive response technology. The EMA guideline EMA/INS/GCP/112288/2023 spells the abbreviation out as “interactive response technologies” in its abbreviation list and treats it as one of several computerised systems that can sit alongside electronic data capture, electronic clinical outcome assessment and eConsent. The same letters are used in other fields, which this page does not cover; the meaning here is the trial-system one.
Definition and scope
An IRT system lets site staff, and sometimes participants or pharmacists, report an event (a participant screened, randomised, a visit completed, a shipment received) and get back an action from the system: a treatment or kit assignment, a dispensing instruction, a resupply decision. The EMA guideline places the IRT in its scope for three jobs: managing randomisation, managing the supply of IMP, and managing receipt of IMP.
The guideline also notes that IRT can be used to collect clinical data from the site. That matters for governance, because anything the IRT captures that feeds the analysis, such as stratification factors, is trial data and needs the same control as data in the electronic data capture system.
An IRT is not the same system as an electronic data capture tool or a clinical trial management system. For how an IRT relates to those systems and to depot-level supply, see the dictionary entry on randomization and trial supply management (RTSM) and the guides on clinical trial supply management and the clinical trial management system.
What is the difference between IRT and IVRS?
IRT is the umbrella term; IVRS (interactive voice response system) and IWRS (interactive web response system) are the access channels. In industry usage IVRS is the original telephone-based form, IWRS its web-based successor, and RTSM (randomisation and trial supply management) is a name often used interchangeably with IRT when the emphasis is on supply. This is vendor and industry convention rather than a regulatory definition, so a protocol or contract should name the system it means. The EMA guideline itself uses “IRT” and describes the example of a web-based application.
The practical consequence is that the regulator’s expectations attach to the function (randomisation, dose assignment, unblinding, supply), not to whether the user dials in or logs in.
How an IRT system is used in a trial
Randomisation and stratification
Under ICH E6(R3) section 2.11, the investigator follows the trial’s randomisation procedures. Where the IRT randomises by user-entered stratification factors, the EMA guideline says all combinations of the strata should be tested to confirm that allocation is occurring from the correct randomisation table. A stratum that was never exercised in testing is a stratum whose allocation was never confirmed.
Dose assignment from site-entered data
Where the IRT assigns a dose from user-entered data such as body surface area or weight, together with look-up tables, the guideline says the tables should be verified against the approved protocol, using test data that includes values on a borderline between differing doses. It describes incorrect dose assignment as a significant risk to safety and wellbeing, and elsewhere identifies an IRT component that calculates IMP dose from investigator-entered data as high risk compared with other functionality.
Supply and receipt of IMP
The supply side is the “supply and receipt of IMP” in the EMA scope statement. The supply functions fall under the same validation principles described below as the rest of the system.
Blinding and emergency unblinding
The EMA guideline states that unblinded information should only be provided and accessible to pre-identified user roles. ICH E6(R3) section 4.1 says sponsor staff and service providers who interact with site staff should not have access to unblinding information except when justified by the trial design, for example unblinded monitors. For the unblinding event itself, see emergency unblinding.
What is the meaning of IRT testing?
In a trial, IRT testing is the verification that the configured system behaves as the protocol requires before it is released for production use. The EMA guideline’s general validation annex (Annex 2) covers user requirements, trial-specific configuration, traceability of requirements, validation and test plans, test execution and reporting, release for production, user helpdesk, periodic review and change control. Annex 5, section A5.2 adds IRT-specific content for when user acceptance test scripts are written.
ICH E6(R3) section 4.3.4 sets the underlying logic: validation is risk-based on intended use, the importance of the data and the potential to affect participants’ wellbeing, rights, safety and the reliability of results; it demonstrates conformity to requirements for completeness, accuracy and reliability; systems are validated before use; both standard functionality and protocol-specific configurations or customisations, including automated checks and calculations, are validated; and interfaces between systems are defined and validated. Later changes are validated on a risk basis under change control.
The EMA guideline also says that where a system’s portal is customised for a trial, robust testing should ensure it is consistent with the approved protocol, giving “randomisation strata and dose calculations in an IRT system” as examples.
Emergency unblinding: test it and plan for failure
Annex 5 expects the emergency unblinding process to be tested and a backup process to exist “in case the online technology emergency unblinding is unavailable”. It also says a site’s ability to perform emergency unblinding should be verified as available before IMP is administered to a participant. ICH E6(R3) section 2.11 puts the matching duty on the investigator: be prepared and capable from the start of the trial to unblind without undue delay and hindrance, and promptly document and explain to the sponsor any premature unblinding, whether accidental, emergency or due to a serious adverse event.
Section 4.1 adds that the potential for unblinding should be part of the risk assessment of a blinded trial, that any planned or unplanned unblinding (including inadvertent or emergency unblinding) should be documented, and that unplanned unblinding should be assessed for its impact on the trial results.
Who is responsible for what
| Party | Responsibility for the IRT | Source |
|---|---|---|
| Sponsor | Keeps a record of important computerised systems (use, functionality, interfaces, validation status, who manages them, access controls, security); addresses validation, audit trails, user management, backup, disaster recovery and IT security through documented procedures and training; the responsible party keeps validation status current across the life cycle | ICH E6(R3), computerised systems and 4.3.4; EMA Annex 1 covers agreements |
| Investigator and site | Follow the randomisation procedure; break the blind only as the protocol allows; be able to unblind without undue delay in an emergency | ICH E6(R3) 2.11 |
| Vendor or service provider | No access to unblinding information unless justified by the trial design; individual accounts, unique user names, least privilege and segregation of duties | ICH E6(R3) 4.1; EMA Annex 3 |
Web-based randomisation lists and reconstruction
The guideline allows web applications to create randomisation lists where justified, provided the sponsor documents the evaluation of suitability, GCP compliance and fitness for purpose, and maintains the version of the service and, where applicable, the seed. It states that ad hoc randomisation via a web service is not recommended, because the distribution is unknown and the sponsor is not in control. Whatever the tool, the sponsor should ensure the randomisation process can be reconstructed from retained documentation and data and that a final randomisation schedule is retained.
When the IRT also collects clinical data
Where the IRT captures clinical data from the site, the guideline says important data, for example stratification data, should be subject to source data verification and/or reconciliation against the same data in the data acquisition tool. If the data flow into the electronic data capture system, the ICH E6 data acquisition requirements (investigator control of site-entered data, authorisation of data changes, and authorisation of persons entering or editing data) should appear in the IRT requirements and be covered by user acceptance testing. The related guide on FDA guidance on electronic systems in clinical investigations covers the US counterpart expectations.
Common misunderstandings
- “IRT is only a randomisation tool.” The EMA scope covers randomisation, supply and receipt of IMP; unblinding control and, in some trials, data collection come with it.
- “A vendor-validated platform needs no trial-specific testing.” Both the EMA guideline and E6(R3) 4.3.4 require protocol-specific configurations, calculations and automated checks to be validated, not only standard functionality.
- “Emergency unblinding is a vendor feature.” The guideline expects it tested, with a backup process, and the investigator is responsible for being able to act without undue delay.
- “IVRS, IWRS, RTSM and IRT are four different regulated categories.” They are industry labels; the regulator’s expectations follow the function.
- “Any unplanned unblinding is only an operations issue.” E6(R3) 4.1 expects it documented and assessed for its impact on the trial results.
Frequently asked questions
What does IRT stand for in research?
Interactive response technology: the computerised system that manages randomisation, supply and receipt of investigational product in a clinical trial, as listed in the EMA guideline on computerised systems in clinical trials.
What is the difference between IRT and IVRS?
IRT is the umbrella term. IVRS is the original telephone-based channel and IWRS the web-based one; RTSM is often used interchangeably with IRT. These are industry conventions, not regulatory definitions.
What is IRT in corporate?
This page covers only the clinical-trial meaning of IRT. For research administrators the relevant system is the one described above, a validated trial system subject to GCP expectations.
What is the meaning of IRT testing?
Testing of the configured IRT before production use: user acceptance test scripts that exercise dose tables, every stratum combination, role-restricted unblinded information and emergency unblinding, as set out in EMA Annex 5 section A5.2 and the validation principles in ICH E6(R3) 4.3.4.
Does an IRT need validation if the vendor already validated its platform?
Yes for the trial-specific parts. The EMA guideline and E6(R3) 4.3.4 expect protocol-specific configuration and customisation, including calculations, to be validated, and the sponsor remains responsible for oversight.
Sources
- European Medicines Agency, Guideline on computerised systems and electronic data in clinical trials, EMA/INS/GCP/112288/2023 (adopted by the GCP Inspectors Working Group on 7 March 2023). Read 2026-11-20.
- ICH, E6(R3) Guideline for Good Clinical Practice, Step 4 (6 January 2025); the EMA-hosted copy is the text the section citations on this page were read from (EMA copy). Read 2026-11-20.
- European Medicines Agency, ICH E6 good clinical practice: scientific guideline. Read 2026-11-20.
- U.S. Food and Drug Administration, E6(R3) Good Clinical Practice (GCP): final guidance for industry that incorporates flexible, risk-based approaches. Read 2026-11-20.
Data: IRT system test and control expectations: EMA computerised-systems guideline mapped to ICH E6(R3)
Cross-walk compiled from two regulatory guidelines: for each IRT function, the testing or control expectation in EMA Annex 5 (A5.2) and related annexes, and the matching ICH E6(R3) section. Rows with no counterpart are marked with a dash.
Period covered: 2023/2025.
| IRT function | EMA guideline expectation | EMA clause | ICH E6(R3) counterpart |
|---|---|---|---|
| Trial-specific configuration | Portal customisation must be consistent with the approved protocol and robustly tested, e.g. randomisation strata and dose calculations | Section on customisation of portals and Annex 2 (A2.3-A2.6) | 4.3.4: standard functionality and protocol-specific configurations validated before use |
| Dose assignment | Verify look-up tables against the protocol; test borderline values between doses; incorrect dosing is a significant safety risk | Annex 5, A5.2 | 4.3.4: automated checks and calculations validated |
| Stratified randomisation | Test all combinations of strata to confirm allocation from the correct randomisation table | Annex 5, A5.2 | 2.11: randomisation procedures followed |
| Access to unblinded information | Provide only to pre-identified user roles | Annex 5, A5.2; Annex 3 (user management) | 4.1: sponsor staff and providers have no unblinding access unless justified by design |
| Emergency unblinding | Test the process, keep a backup if the online route is unavailable, verify site ability before IMP is administered | Annex 5, A5.2 | 2.11: investigator able to unblind without undue delay; premature unblinding documented |
| Unplanned unblinding | Not stated as a separate item in A5.2 | - | 4.1: document any unblinding and assess impact on trial results |
| Clinical data captured in IRT | Source data verification and/or reconciliation with the data acquisition tool; E6 data-acquisition requirements in IRT requirements and UAT | Annex 5, A5.2 | 4.3.4: interfaces between systems defined and validated |
| Web-based randomisation lists | Document suitability, GCP compliance and fitness for purpose; keep service version and seed; ad hoc web randomisation not recommended | Annex 5, A5.2 | - |
| Reconstruction of randomisation | Process reconstructable from retained documentation and data; final randomisation schedule retained | Annex 5, A5.2 | - |
Sources
- EMA Guideline on computerised systems and electronic data in clinical trials (EMA/INS/GCP/112288/2023) (accessed 2026-11-20)
- ICH E6(R3) Guideline for Good Clinical Practice (accessed 2026-11-20)
Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.







